What is Microvisk?
Microvisk Technologies is dedicated to advancing patient care through the development of cutting-edge medical devices for anticoagulation monitoring. Leveraging proprietary Micro Electro Mechanical Sensors (MEMS) technology, the company's CoagMax PT/INR System offers precise and user-friendly testing solutions for both at-home use and point-of-care settings. This innovation is particularly crucial for individuals undergoing anticoagulant therapy and for healthcare providers seeking efficient diagnostic tools. Established in 2004 and headquartered in Oxford, UK, Microvisk operates under stringent ISO 13485:2016 quality standards, reflecting its commitment to medical device excellence.
How much funding has Microvisk raised?
Microvisk has raised a total of $22.9M across 3 funding rounds:
Series A
$3.9M
Series C
$9.5M
Series B
$9.5M
Series A (2010): $3.9M with participation from Oxford Technology Management and Finance Wales
Series C (2011): $9.5M, investors not publicly disclosed
Series B (2011): $9.5M supported by Oxford Technology and New Hill Management
Key Investors in Microvisk
Oxford Technology Management
Oxford Technology Management is an investment firm focused on early-stage technology startups, providing capital and support to foster innovation, particularly within the UK's technology sector.
Finance Wales
Finance Wales, now part of the Development Bank of Wales, offers crucial business finance and investment solutions to companies in Wales, supporting growth and innovation across various sectors, including technology.
New Hill Management
New Hill Management is an entity involved in providing capital for business ventures, likely focusing on strategic growth and development opportunities within its investment portfolio.
What's next for Microvisk?
The recent major strategic investment signals a critical phase for Microvisk, likely aimed at scaling its manufacturing capabilities, expanding market reach, and further developing its innovative MEMS-based diagnostic platforms. This capital infusion is expected to accelerate the company's trajectory, potentially leading to broader adoption of its CoagMax system within the global healthcare market and solidifying its position as a key player in remote patient monitoring and diagnostics. Further strategic partnerships or product line expansions may follow as the company capitalizes on this significant backing.
See full Microvisk company page
